Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T12:20:28.011Z Has data issue: false hasContentIssue false
  • English
  • Français

Haematological monitoring for clozapine: do patients know why?

Published online by Cambridge University Press:  02 January 2018

Carol Paton  and
Paul Wolfson
Carol Paton*
Affiliation:
Bexley Hospital Old Bexley bane, Bexley, Kent DA5 2BW
Paul Wolfson
Affiliation:
Bexley Hospital Old Bexley bane, Bexley, Kent DA5 2BW
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Clozapine is effective in treatment resistant schizophrenia, but unfortunately is associated with a 3% incidence of neutropenia. Regular haematological monitoring is mandatory for all patients. We asked forty patients who had been taking clozapine for more than six months why they thought they had to have regular blood tests. Almost half did not know and only a small proportion were subject to a Mental Health Act (MHA) second opinion for consent to treatment. Initial explanations of the potentially serious side effects of clozapine may not be understood or retained. Ongoing education of patients is essential. The wider use of MHA second opinion doctors should also be considered.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 19 , Issue 9 , September 1995 , pp. 536 - 537
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1995

References

Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, revised DHEW Pub. No. (ADM) 78–388, Rockville, MD: National Institute of Mental Health.Google Scholar
Jeffries, J. J. (1993) Ethical issues in drug selection for schizophrenia. Canadian Journal of Psychiatry, 38 (suppl. 3), 70–74.Google Scholar
Kane, J. M. (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. British Journal of Psychiatry, 160 (suppl. 17), 41–45.Google Scholar
Mental Health Act Commission (1993) Guidance on the administration of clozapine and other treatments requiring blood tests under the provisions of part IV of the Mental Health Act. Practice note 1.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.